Lantern Pharma (NasdaqCM:LTRN) Update / Briefing Transcript

Lantern Pharma (NasdaqCM:LTRN) Update / Briefing November 20, 2025 04:30 PM ET Speaker1Okay. Thank you, everyone, for joining us today for our LP-184 clinical trial results webinar. We'll be talking in depth today with some of our Lantern Pharma team and also with our collaborator and partner in developing the trial and some of the early science behind LP-184. Dr. Igor Astsaturov from Fox Chase is also on with us as well. I'm going to be talking about, overall, the drug, just to give everyone an overview of ...